GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Common Stock

DNTH (Dianthus Therapeutics) Common Stock : $0.03 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Common Stock?

Dianthus Therapeutics's quarterly common stock stayed the same from Jun. 2024 ($0.03 Mil) to Sep. 2024 ($0.03 Mil) but then increased from Sep. 2024 ($0.03 Mil) to Dec. 2024 ($0.03 Mil).

Dianthus Therapeutics's annual common stock increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.02 Mil) and increased from Dec. 2023 ($0.02 Mil) to Dec. 2024 ($0.03 Mil).


Dianthus Therapeutics Common Stock Historical Data

The historical data trend for Dianthus Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Common Stock Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Common Stock
- - 0.02 0.03

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.03 0.03 0.03

Dianthus Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Dianthus Therapeutics Business Description

Traded in Other Exchanges
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.